A recombinant bovine herpesvirus 5 defective in thymidine kinase and glycoprotein E is immunogenic for calves and confers protection upon homologous challenge and BoHV-1 challenge

作者：Anziliero D; Santos C M B; Brum M C S; Weiblen R; Chowdhury S I; Flores E F^*

来源：Veterinary Microbiology, 2011, 154(1-2): 14-22.

DOI：10.1016/j.vetmic.2011.03.019

• BoHV-5
• Bovine herpesvirus
• Vaccine
• DIVA
• Recombinant

A recombinant bovine herpesvirus 5 lacking thymidine kinase and glycoprotein E genes (BoHV-5gE Delta TK Delta) was evaluated as a live experimental vaccine. In a first experiment, ten-months-old calves were vaccinated intramuscularly (n = 9) or remained as controls (n = 8) and 42 days later were challenged with BoHV-5 or BoHV-1 intranasally. The four control calves challenged with BoHV-5 developed severe depression and neurological signs and were euthanized in extremis at days 13 and 14 pos-infection (pi); the five vaccinated animals challenged with BoHV-5 remained healthy. The titers of virus shedding were reduced (p < 0.01) from days 3 to 7 post-infection (pi) in vaccinated animals. Control and vaccinated calves challenged with BoHV-1 presented mild transient respiratory signs; yet the magnitude of virus shedding was reduced (p < 0.05) in vaccinated animals (days 5, 9 and 11 pi). In a second experiment, young calves (100-120 days-old) were vaccinated (n = 15) or kept as controls (n = 5) and subsequently challenged with a BoHV-1 isolate. Control calves developed moderate to severe rhinitis and respiratory distress; two were euthanized in extremis at days 5 and 9 pi, respectively. In contrast, vaccinated animals were protected from challenge and only a few developed mild and transient nasal signs. The duration and titers of virus shedding after challenge were reduced (p < 0.05) in vaccinated animals comparing to controls. In both experiments, vaccinated animals developed antibodies to gE only after challenge. These results demonstrate homologous and heterologous protection and are promising towards the use of the recombinant BoHV-5gE Delta TK Delta in vaccine formulations to control BoHV-5 and BoHV-1 infections.

• 出版日期2011-12-29